GlassScriptPhysician profile
Gerald V Mcmahon
NPI 1356369060
$3,759.83
in general payments reported to CMS, 2019-2025
51 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $166 · 2021: $238 · 2022: $53.05 · 2023: $987 · 2024: $942 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,023.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $273.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $243.14 | 2019-2025 | |
| Abbott Laboratories | $199.20 | 2022-2025 | Freestyle Libre 3, Assurity, Freestyle Libre 2 |
| Lilly USA, LLC | $192.08 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $170.01 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.18 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lundbeck LLC | $160.41 | 2023-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $156.08 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $149.93 | 2019-2025 | Repatha, Evenity, Repatha |
| Abbvie INC. | $118.94 | 2021-2025 | |
| Emd Serono, INC. | $114.52 | 2023-2025 | Mavenclad |
| Amarin Pharma, INC. | $112.16 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $108.28 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Merck Sharp & Dohme LLC | $99.86 | 2019-2023 | Gardasil 9, Verquvo, Varivax |
| Genentech USA, INC. | $89.11 | 2023-2024 | Ocrevus |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.